

REFERENCES

1. Schmitz, G., and J. Ecker. 2008. The opposing effects of n-3 and n-6 fatty acids. *Prog Lipid Res* 47:147-155.
2. Dyall, S. C., and A. T. Michael-Titus. 2008. Neurological benefits of omega-3 fatty acids. *Neuromolecular Med* 10:219-235.
3. Taketo, M. M., and M. Sonoshita. 2002. Phospholipase A2 and apoptosis. *Biochim Biophys Acta* 1585:72-76.
4. Caro, A. A., and A. I. Cederbaum. 2006. Role of cytochrome P450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity. *Free Radic Biol Med* 40:364-375.
5. Tilley, S. L., T. M. Coffman, and B. H. Koller. 2001. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest* 108:15-23.
6. Pompeia, C., T. Lima, and R. Curi. 2003. Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death? *Cell Biochem Funct* 21:97-104.
7. Nakanishi, M., and D. W. Rosenberg. 2006. Roles of cPLA2alpha and arachidonic acid in cancer. *Biochim Biophys Acta* 1761:1335-1343.
8. Cook, J. A. 2005. Eicosanoids. *Crit Care Med* 33:S488-491.
9. Bonventre, J. 2004. Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption. *Trends Immunol* 25:116-119.
10. Martel-Pelletier, J., J. P. Pelletier, and H. Fahmi. 2003. Cyclooxygenase-2 and prostaglandins in articular tissues. *Semin Arthritis Rheum* 33:155-167.
11. Ribardo, D. A., S. E. Crowe, K. R. Kuhl, J. W. Peterson, and A. K. Chopra. 2001. Prostaglandin levels in stimulated macrophages are controlled by phospholipase A2-activating protein and by activation of phospholipase C and D. *J Biol Chem* 276:5467-5475.
12. Oestvang, J., and B. Johansen. 2006. PhospholipaseA2: a key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. *Biochim Biophys Acta* 1761:1309-1316.
13. FitzGerald, G. A. 2003. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. *Nat Rev Drug Discov* 2:879-890.
14. Bazan, N. G., V. Colangelo, and W. J. Lukiw. 2002. Prostaglandins and other lipid mediators in Alzheimer's disease. *Prostaglandins Other Lipid Mediat* 68-69:197-210.
15. Wang, D., and R. N. Dubois. 2006. Prostaglandins and cancer. *Gut* 55:115-122.
16. Bertsch, T., and J. Aufenanger. 1997. Phospholipase A2 in inflammatory bowel disease. *Gut* 41:859-860.
17. Bomalaski, J. S., and M. A. Clark. 1993. Phospholipase A2 and arthritis. *Arthritis Rheum* 36:190-198.
18. Chakraborti, S. 2003. Phospholipase A(2) isoforms: a perspective. *Cell Signal* 15:637-665.
19. Scott, K. F., K. J. Bryant, and M. J. Bidgood. 1999. Functional coupling and differential regulation of the phospholipase A2-cyclooxygenase pathways in inflammation. *J Leukoc Biol* 66:535-541.

20. Balsinde, J., R. Perez, and M. A. Balboa. 2006. Calcium-independent phospholipase A2 and apoptosis. *Biochim Biophys Acta* 1761:1344-1350.
21. Lindstrom, T., and P. Bennett. 2004. Transcriptional regulation of genes for enzymes of the prostaglandin biosynthetic pathway. *Prostaglandins Leukot Essent Fatty Acids* 70:115-135.
22. Kronke, M., and S. Adam-Klages. 2002. Role of caspases in TNF-mediated regulation of cPLA(2). *FEBS Lett* 531:18-22.
23. Cummings, B. S., J. McHowat, and R. G. Schnellmann. 2004. Role of an endoplasmic reticulum Ca²⁺-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. *J Pharmacol Exp Ther* 308:921-928.
24. Ribardo, D. A., J. W. Peterson, and A. K. Chopra. 2002. Phospholipase A2-activating protein--an important regulatory molecule in modulating cyclooxygenase-2 and tumor necrosis factor production during inflammation. *Indian J Exp Biol* 40:129-138.
25. Ribardo, D. A., K. R. Kuhl, J. W. Peterson, and A. K. Chopra. 2002. Role of melittin-like region within phospholipase A(2)-activating protein in biological function. *Toxicon* 40:519-526.
26. Clark, M. A., L. E. Ozgur, T. M. Conway, J. Dispoto, S. T. Croke, and J. S. Bomalaski. 1991. Cloning of a phospholipase A2-activating protein. *Proc Natl Acad Sci U S A* 88:5418-5422.
27. Clark, M. A., T. M. Conway, R. G. Shorr, and S. T. Croke. 1987. Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. *J Biol Chem* 262:4402-4406.
28. Wang, H., J. J. Lemasters, and B. Herman. 1995. Cloning of a rat cDNA encoding a protein with high homology to mouse phospholipase A2-activating protein. *Gene* 161:237-241.
29. Chopra, A. K., D. A. Ribardo, T. G. Wood, D. J. Prusak, X. J. Xu, and J. W. Peterson. 1999. Molecular characterization of cDNA for phospholipase A2-activating protein. *Biochim Biophys Acta* 1444:125-130.
30. Drin, G., and S. Scarlata. 2007. Stimulation of phospholipase Cbeta by membrane interactions, interdomain movement, and G protein binding--how many ways can you activate an enzyme? *Cell Signal* 19:1383-1392.
31. Peterson, J. W., S. S. Saini, W. D. Dickey, G. R. Klimpel, J. S. Bomalaski, M. A. Clark, X. J. Xu, and A. K. Chopra. 1996. Cholera toxin induces synthesis of phospholipase A2-activating protein. *Infect Immun* 64:2137-2143.
32. Homaidan, F. R., L. Zhao, and R. Burakoff. 1997. IL-1 beta induces synthesis of phospholipase A2-activating protein in rabbit distal colon. *Am J Physiol* 272:G1338-1346.
33. PLAA_EST_Profile_Viewer. The expression profile of Phospholipase A2-activating protein (Hs.27182) obtained from Expressed Sequence Tag (EST) counts. <http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.27182>. Retrieved on December 2nd, 2008.
34. Bomalaski, J. S., D. G. Baker, L. M. Brophy, and M. A. Clark. 1990. Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein. *J Immunol* 145:3391-3397.

- Reichrath. 2006. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. *Cell Death Differ* 13:12-19.
48. Goda, C., T. Kanaji, S. Kanaji, G. Tanaka, K. Arima, S. Ohno, and K. Izuhara. 2006. Involvement of IL-32 in activation-induced cell death in T cells. *Int Immunol* 18:233-240.
 49. Zhang, F., J. Sha, T. G. Wood, C. L. Galindo, H. R. Garner, M. F. Burkart, G. Suarez, J. C. Sierra, S. L. Agar, J. W. Peterson, and A. K. Chopra. 2008. Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA). *Cell Signal* 20:844-861.
 50. Zhang, H., J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, and N. M. Dean. 2000. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. *Nat Biotechnol* 18:862-867.
 51. Steinke, J. W., and L. Borish. 2006. 3. Cytokines and chemokines. *J Allergy Clin Immunol* 117:S441-445.
 52. Lio, Y. C., L. J. Reynolds, J. Balsinde, and E. A. Dennis. 1996. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. *Biochim Biophys Acta* 1302:55-60.
 53. Schaloske, R. H., and E. A. Dennis. 2006. The phospholipase A2 superfamily and its group numbering system. *Biochim Biophys Acta* 1761:1246-1259.
 54. Liu, T., W. Zaman, B. S. Kaphalia, G. A. Ansari, R. P. Garofalo, and A. Casola. 2005. RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. *Virology* 343:12-24.
 55. Choi, S. H., R. Langenbach, and F. Bosetti. 2006. Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis. *J Neurochem* 98:801-811.
 56. Balsinde, J., I. D. Bianco, E. J. Ackermann, K. Conde-Frieboes, and E. A. Dennis. 1995. Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proc Natl Acad Sci U S A* 92:8527-8531.
 57. Lister, M. D., K. B. Glaser, R. J. Ulevitch, and E. A. Dennis. 1989. Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide. *J Biol Chem* 264:8520-8528.
 58. Plesniak, L. A., S. C. Boegeman, B. W. Segelke, and E. A. Dennis. 1993. Interaction of phospholipase A2 with thioether amide containing phospholipid analogues. *Biochemistry* 32:5009-5016.
 59. Dai, R. M., E. Chen, D. L. Longo, C. M. Gorbea, and C. C. Li. 1998. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. *J Biol Chem* 273:3562-3573.
 60. Ishibashi, H., K. Nakagawa, M. Onimaru, E. J. Castellanos, Y. Kaneda, Y. Nakashima, K. Shirasuna, and K. Sueishi. 2000. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and

- invasion activities. *Cancer Res* 60:6531-6536.
61. Grabe, N. 2002. AliBaba2: context specific identification of transcription factor binding sites. *In Silico Biol* 2:S1-15.
 62. Romisch, J., M. Grote, K. U. Weithmann, N. Heimburger, and E. Amann. 1990. Annexin proteins PP4 and PP4-X. Comparative characterization of biological activities of placental and recombinant proteins. *Biochem J* 272:223-229.
 63. Gerke, V., C. E. Creutz, and S. E. Moss. 2005. Annexins: linking Ca²⁺ signalling to membrane dynamics. *Nat Rev Mol Cell Biol* 6:449-461.
 64. Kuwata, H., Y. Nakatani, M. Murakami, and I. Kudo. 1998. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. *J Biol Chem* 273:1733-1740.
 65. Fadl, A. A., C. L. Galindo, J. Sha, F. Zhang, H. R. Garner, H. Q. Wang, and A. K. Chopra. 2007. Global transcriptional responses of wild-type *Aeromonas hydrophila* and its virulence-deficient mutant in a murine model of infection. *Microb Pathog* 42:193-203.
 66. Funk, C. D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* 294:1871-1875.
 67. Bergeron, J. J., M. B. Brenner, D. Y. Thomas, and D. B. Williams. 1994. Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. *Trends Biochem Sci* 19:124-128.
 68. Kim, S. H., S. Y. Han, T. Azam, D. Y. Yoon, and C. A. Dinarello. 2005. Interleukin-32: a cytokine and inducer of TNF α . *Immunity* 22:131-142.
 69. Joosten, L. A., M. G. Netea, S. H. Kim, D. Y. Yoon, B. Oppers-Walgreen, T. R. Radstake, P. Barrera, F. A. van de Loo, C. A. Dinarello, and W. B. van den Berg. 2006. IL-32, a proinflammatory cytokine in rheumatoid arthritis. *Proc Natl Acad Sci U S A* 103:3298-3303.
 70. Mastorakos, G., and I. Ilias. 2006. Interleukin-6: a cytokine and/or a major modulator of the response to somatic stress. *Ann N Y Acad Sci* 1088:373-381.
 71. Devauchelle, V., A. Essabbani, G. De Pinieux, S. Germain, L. Tourneur, S. Mistou, F. Margottin-Goguet, P. Anract, H. Migaud, D. Le Nen, T. Lequerre, A. Saraux, M. Dougados, M. Breban, C. Fournier, and G. Chiochia. 2006. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. *J Immunol* 177:6471-6479.
 72. Santilli, G., B. J. Aronow, and A. Sala. 2003. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. *J Biol Chem* 278:38214-38219.
 73. Trougakos, I. P., and E. S. Gonos. 2006. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. *Free Radic Res* 40:1324-1334.
 74. Tsuchiya, Y., K. Yabe, S. Takada, Y. Ishii, T. Jindo, K. Furuhashi, and K. T. Suzuki. 2005. Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam. *Toxicol Pathol* 33:561-569.
 75. Tsuchiya, Y., Y. Tominaga, K. Matsubayashi, T. Jindo, K. Furuhashi, and K. T. Suzuki. 2005. Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam. *Arch Toxicol* 79:500-507.

76. Blaine, S. A., M. Wick, C. Dessev, and R. A. Nemenoff. 2001. Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun. *J Biol Chem* 276:42737-42743.
77. Antonio, V., A. Brouillet, B. Janvier, C. Monne, G. Bereziat, M. Andreani, and M. Raymondjean. 2002. Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. *Biochem J* 368:415-424.
78. Wu, X., G. A. Zimmerman, S. M. Prescott, and D. M. Stafforini. 2004. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. *J Biol Chem* 279:36158-36165.
79. Chang, W. C., and B. K. Chen. 2005. Transcription factor Sp1 functions as an anchor protein in gene transcription of human 12(S)-lipoxygenase. *Biochem Biophys Res Commun* 338:117-121.
80. Devauchelle, V., S. Marion, N. Cagnard, S. Mistou, G. Falgarone, M. Breban, F. Letourneur, A. Pitaval, O. Alibert, C. Lucchesi, P. Anract, M. Hamadouche, X. Ayrat, M. Dougados, X. Gidrol, C. Fournier, and G. Chiochia. 2004. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. *Genes Immun* 5:597-608.
81. Rioja, I., C. L. Clayton, S. J. Graham, P. F. Life, and M. C. Dickson. 2005. Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis. *Arthritis Res Ther* 7:R101-117.
82. Cagnard, N., F. Letourneur, A. Essabani, V. Devauchelle, S. Mistou, A. Rapinat, C. Decraene, C. Fournier, and G. Chiochia. 2005. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. *Eur Cytokine Netw* 16:289-292.
83. van der Pouw Kraan, T. C., F. A. van Gaalen, P. V. Kasperkovitz, N. L. Verbeet, T. J. Smeets, M. C. Kraan, M. Fero, P. P. Tak, T. W. Huizinga, E. Pieterman, F. C. Breedveld, A. A. Alizadeh, and C. L. Verweij. 2003. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. *Arthritis Rheum* 48:2132-2145.
84. Parente, L., and E. Solito. 2004. Annexin 1: more than an anti-phospholipase protein. *Inflamm Res* 53:125-132.
85. Shioya, M., A. Nishida, Y. Yagi, A. Ogawa, T. Tsujikawa, S. Kim-Mitsuyama, A. Takayanagi, N. Shimizu, Y. Fujiyama, and A. Andoh. 2007. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. *Clin Exp Immunol*.
86. Netea, M. G., T. Azam, G. Ferwerda, S. E. Girardin, M. Walsh, J. S. Park, E. Abraham, J. M. Kim, D. Y. Yoon, C. A. Dinarello, and S. H. Kim. 2005. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. *Proc Natl Acad Sci U S A* 102:16309-16314.
87. Anthonsen, M. W., A. Solhaug, and B. Johansen. 2001. Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis

- factor-alpha- and interleukin-1beta-induced NF-kappa B activation. *J Biol Chem* 276:30527-30536.
88. Poligone, B., and A. S. Baldwin. 2001. Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. *J Biol Chem* 276:38658-38664.
 89. Seigneurin-Berny, D., A. Verdel, S. Curtet, C. Lemerrier, J. Garin, S. Rousseaux, and S. Khochbin. 2001. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. *Mol Cell Biol* 21:8035-8044.
 90. Rumpf, S., and S. Jentsch. 2006. Functional division of substrate processing cofactors of the ubiquitin-selective Cdc48 chaperone. *Mol Cell* 21:261-269.
 91. Tatusova, T. A., and T. L. Madden. 1999. BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. *FEMS Microbiol Lett* 174:247-250.
 92. Bonventre, J. V., Z. Huang, M. R. Taheri, E. O'Leary, E. Li, M. A. Moskowitz, and A. Sapirstein. 1997. Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A2. *Nature* 390:622-625.
 93. Lim, H., B. C. Paria, S. K. Das, J. E. Dinchuk, R. Langenbach, J. M. Trzaskos, and S. K. Dey. 1997. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. *Cell* 91:197-208.
 94. Challis, J. R. 1997. Prostaglandins and reproduction--what do knockouts really tell us? *Nat Med* 3:1326-1327.
 95. Han, C., A. J. Demetris, D. B. Stolz, L. Xu, K. Lim, and T. Wu. 2006. Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. *J Biol Chem* 281:24831-24846.
 96. Bouwman, P., and S. Philipsen. 2002. Regulation of the activity of Sp1-related transcription factors. *Mol Cell Endocrinol* 195:27-38.
 97. Perkins, N. D., N. L. Edwards, C. S. Duckett, A. B. Agranoff, R. M. Schmid, and G. J. Nabel. 1993. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. *Embo J* 12:3551-3558.
 98. Hirano, F., H. Tanaka, Y. Hirano, M. Hiramoto, H. Handa, I. Makino, and C. Scheidereit. 1998. Functional interference of Sp1 and NF-kappaB through the same DNA binding site. *Mol Cell Biol* 18:1266-1274.
 99. Kracht, M., and J. Saklatvala. 2002. Transcriptional and post-transcriptional control of gene expression in inflammation. *Cytokine* 20:91-106.
 100. Wang, D., and S. J. Lippard. 2005. Cellular processing of platinum anticancer drugs. *Nat Rev Drug Discov* 4:307-320.
 101. Boulikas, T., and M. Vougiouka. 2004. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). *Oncol Rep* 11:559-595.
 102. Siddik, Z. H. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* 22:7265-7279.
 103. Rybak, L. P., C. A. Whitworth, D. Mukherjea, and V. Ramkumar. 2007. Mechanisms of cisplatin-induced ototoxicity and prevention. *Hear Res* 226:157-167.
 104. Yao, X., K. Panichpisal, N. Kurtzman, and K. Nugent. 2007. Cisplatin nephrotoxicity: a review. *Am J Med Sci* 334:115-124.

105. Gonzalez, V. M., M. A. Fuertes, C. Alonso, and J. M. Perez. 2001. Is cisplatin-induced cell death always produced by apoptosis? *Mol Pharmacol* 59:657-663.
106. Hertelendy, F., and T. Zakar. 2004. Prostaglandins and the myometrium and cervix. *Prostaglandins Leukot Essent Fatty Acids* 70:207-222.
107. Schaffert, N., M. Hossbach, R. Heintzmann, T. Achsel, and R. Luhrmann. 2004. RNAi knockdown of hPrp31 leads to an accumulation of U4/U6 di-snRNPs in Cajal bodies. *Embo J* 23:3000-3009.
108. Zha, S., S. Ferdinandusse, S. Denis, R. J. Wanders, C. M. Ewing, J. Luo, A. M. De Marzo, and W. B. Isaacs. 2003. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. *Cancer Res* 63:7365-7376.
109. van den Hoff, M. J., A. F. Moorman, and W. H. Lamers. 1992. Electroporation in 'intracellular' buffer increases cell survival. *Nucleic Acids Res* 20:2902.
110. Vyatkina, G., V. Bhatia, A. Gerstner, J. Papaconstantinou, and N. Garg. 2004. Impaired mitochondrial respiratory chain and bioenergetics during chagasic cardiomyopathy development. *Biochim Biophys Acta* 1689:162-173.
111. Sierra, J. C., G. Suarez, J. Sha, S. M. Foltz, V. L. Popov, C. L. Galindo, H. R. Garner, and A. K. Chopra. 2007. Biological characterization of a new type III secretion system effector from a clinical isolate of *Aeromonas hydrophila*-part II. *Microb Pathog* 43:147-160.
112. Riedl, S. J., and Y. Shi. 2004. Molecular mechanisms of caspase regulation during apoptosis. *Nat Rev Mol Cell Biol* 5:897-907.
113. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 65:55-63.
114. Sintich, S. M., J. Steinberg, J. M. Kozlowski, C. Lee, S. Pruden, S. Sayeed, and J. A. Sensibar. 1999. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). *Prostate* 39:87-93.
115. Lourda, M., I. P. Trougakos, and E. S. Gonos. 2007. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. *Int J Cancer* 120:611-622.
116. Shaulian, E., and M. Karin. 2002. AP-1 as a regulator of cell life and death. *Nat Cell Biol* 4:E131-136.
117. Brozovic, A., and M. Osmak. 2007. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. *Cancer Lett* 251:1-16.
118. Mansouri, A., L. D. Ridgway, A. L. Korapati, Q. Zhang, L. Tian, Y. Wang, Z. H. Siddik, G. B. Mills, and F. X. Claret. 2003. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. *J Biol Chem* 278:19245-19256.
119. Liu, X., H. Zou, C. Slaughter, and X. Wang. 1997. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. *Cell* 89:175-184.
120. McLaughlin, L., G. Zhu, M. Mistry, C. Ley-Ebert, W. D. Stuart, C. J. Florio, P. A. Groen, S. A. Witt, T. R. Kimball, D. P. Witte, J. A. Harmony, and B. J. Aronow. 2000. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. *J Clin Invest* 106:1105-1113.
121. Zhang, H., J. K. Kim, C. A. Edwards, Z. Xu, R. Taichman, and C. Y. Wang. 2005.

